CD86 and neoplasm: After administering the in situ gel vaccine with or withoutanti-PD-1 antibody in the gel (Dox-cGAMPnp@Gel or aPD1-Dox-cGAMPnp@Gel),we found that the number of tumor-infiltrating DCs did not changein either model (Figure 8B), but there was a significant increase in their activation (CD86+MHCII+) (Figure 8C).